OncoResponse Obtains $19,499,000 New Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e92d4f7c-0c05-4dcb-9813-61762999fc1f
Date
5/26/2016
Company Name
OncoResponse
Mailing Address
909 Fannin Houston, TX 77024 USA
Company Description
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery.
Website
http://www.oncoresponseinc.com
Transaction Type
Venture Equity
Transaction Amount
$19,499,000
Transaction Round
Undisclosed
Proceeds Purposes
The investment by Baxalta brings the total Series A to $12.5 million and will be used to support OncoResponse’s ongoing efforts to interrogate the humoral response of elite responders to cancer immunotherapy to identify antibodies and potential targets for novel therapeutic development.
M&A Terms
Venture Investor
Baxalta Ventures
Venture Investor
Undisclosed